Literature DB >> 17065627

Telithromycin-nonsusceptible clinical isolates of Streptococcus pneumoniae from Europe.

Adnan Al-Lahham1, Peter C Appelbaum, Mark van der Linden, Ralf René Reinert.   

Abstract

Telithromycin-nonsusceptible pneumococcal clinical isolates (n = 17) were analyzed for their antimicrobial susceptibility, macrolide resistance mechanisms, and genetic relatedness. All strains showed the erm(B) genotype and showed a wide range of combinations of macrolide resistance mechanisms. The predominant clone (n = 7) was serotype 14, sequence type 143.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17065627      PMCID： PMC1635229          DOI： 10.1128/AAC.00057-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  Characterization of German penicillin non-susceptible serotype 23F pneumococci using multilocus sequence typing.

Authors:  Ralf René Reinert; Stefanie Muckel; Adnan Al-Lahham; Brian G Spratt; Angela B Brueggemann; Regine Hakenbeck; Rudolf Lütticken
Journal:  J Med Microbiol       Date:  2003-11       Impact factor: 2.472

2.  Streptococcus pneumoniae isolates resistant to telithromycin.

Authors:  M Rantala; M Haanperä-Heikkinen; M Lindgren; H Seppälä; P Huovinen; J Jalava
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

3.  Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae.

Authors:  Annie Canu; Brigitte Malbruny; Maëlle Coquemont; Todd A Davies; Peter C Appelbaum; Roland Leclercq
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

Review 4.  Resistance among Streptococcus pneumoniae: Implications for drug selection.

Authors:  Peter C Appelbaum
Journal:  Clin Infect Dis       Date:  2002-05-16       Impact factor: 9.079

5.  Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage.

Authors:  A Tait-Kamradt; T Davies; M Cronan; M R Jacobs; P C Appelbaum; J Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

Review 6.  Drugs of the 21st century: telithromycin (HMR 3647)--the first ketolide.

Authors:  Grit Ackermann; Arne C Rodloff
Journal:  J Antimicrob Chemother       Date:  2003-03       Impact factor: 5.790

7.  Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003.

Authors:  David J Farrell; David Felmingham
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

8.  High-level telithromycin resistance in laboratory-generated mutants of Streptococcus pneumoniae.

Authors:  Fiona Walsh; Joanne Willcock; Sebastian Amyes
Journal:  J Antimicrob Chemother       Date:  2003-08-13       Impact factor: 5.790

9.  Molecular characterisation of macrolide resistance mechanisms of Streptococcus pneumoniae and Streptococcus pyogenes isolated in Germany, 2002-2003.

Authors:  Ralf René Reinert; Carmen Franken; Mark van der Linden; Rudolf Lütticken; Murat Cil; Adnan Al-Lahham
Journal:  Int J Antimicrob Agents       Date:  2004-07       Impact factor: 5.283

10.  Ribosomal mutations conferring resistance to macrolides in Streptococcus pneumoniae clinical strains isolated in Germany.

Authors:  Ralf René Reinert; Angela Wild; Peter Appelbaum; Rudolf Lütticken; Murat Yücel Cil; Adnan Al-Lahham
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191
View more
  4 in total

1.  High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae.

Authors:  Nicole Wolter; Anthony M Smith; Donald E Low; Keith P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2007-01-08       Impact factor: 5.191

2.  Kinetics of drug-ribosome interactions defines the cidality of macrolide antibiotics.

Authors:  Maxim S Svetlov; Nora Vázquez-Laslop; Alexander S Mankin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-11       Impact factor: 11.205

3.  In vitro antibacterial activity of modithromycin, a novel 6,11-bridged bicyclolide, against respiratory pathogens, including macrolide-resistant Gram-positive cocci.

Authors:  Takafumi Sato; Kazuhiro Tateda; Soichiro Kimura; Morihiro Iwata; Yoshikazu Ishii; Keizo Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191

Review 4.  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Authors:  Françoise Van Bambeke; René R Reinert; Peter C Appelbaum; Paul M Tulkens; Willy E Peetermans
Journal:  Drugs       Date:  2007       Impact factor: 9.546
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.